These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23728011)

  • 21. Left atrial appendage closure.
    Lin AC; Knight BP
    Prog Cardiovasc Dis; 2015; 58(2):195-201. PubMed ID: 26241302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation.
    Fernandez MM; von Schéele B; Hogue S; Kwong WJ
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):87-102. PubMed ID: 23572283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
    Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
    Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
    Garcia DA
    Thromb Res; 2012 Jan; 129(1):9-16. PubMed ID: 22018997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Namibia becomes first country in Africa to launch dabigatran etexilate for atrial fibrillation.
    Wagenaar P
    Cardiovasc J Afr; 2011; 22(5):283. PubMed ID: 21983957
    [No Abstract]   [Full Text] [Related]  

  • 26. Atrial fibrillation: stroke prevention in older adults.
    Quinn GR; Fang MC
    Clin Geriatr Med; 2012 Nov; 28(4):617-34. PubMed ID: 23101573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment.
    Sennesael AL; Dogné JM; Spinewine A
    JAMA Intern Med; 2015 Oct; 175(10):1608-9. PubMed ID: 26237648
    [No Abstract]   [Full Text] [Related]  

  • 28. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
    Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
    J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MY APPROACH to arial fibrillation patients with a bleeding risk.
    Holmes DR
    Trends Cardiovasc Med; 2016 Jul; 26(5):477-8. PubMed ID: 27017443
    [No Abstract]   [Full Text] [Related]  

  • 30. Renal profiles of anticoagulants.
    Harder S
    J Clin Pharmacol; 2012 Jul; 52(7):964-75. PubMed ID: 21610202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants.
    Miyazawa K; Pastori D; Lip GYH
    Am Heart J; 2018 Apr; 198():166-168. PubMed ID: 29653639
    [No Abstract]   [Full Text] [Related]  

  • 32. Ineligibility for anticoagulation in patients with atrial fibrillation.
    del Conde I; Halperin JL
    Am J Med; 2013 Feb; 126(2):105-11. PubMed ID: 23331435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.
    Salim I; Al Suwaidi J; Ghadban W; Salam AM
    Expert Opin Drug Saf; 2013 Jan; 12(1):53-63. PubMed ID: 23095103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
    Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anticoagulation in polypathological patients with atrial fibrillation].
    Díez-Manglano J; Bernabeu-Wittel M; Barón-Franco B; Murcia-Zaragoza J; Fuertes Martín A; Alemán A; Ollero-Baturone M;
    Med Clin (Barc); 2013 Feb; 140(3):97-103. PubMed ID: 23199837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. To anticoagulate or not to anticoagulate? - New insights into a common question.
    Fischer AJ; Freisinger E
    Vasa; 2016; 45(2):186. PubMed ID: 27058807
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
    Själander A; Wallentin L; Rosenqvist M; Svensson P
    Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.